Professor McCance-Katz is the Chief Medical Officer for the Substance Abuse and Mental Health Services Administration (SAMHSA). She is board-certified in General Psychiatry and Addiction Psychiatry and is a Distinguished Fellow of the American Academy of Addiction Psychiatry. Dr McCance-Katz has been working in the fields of psychiatry and addiction medicine for 23 years as a clinician, teacher, and clinical researcher. Her specialty areas include co-occurring mental/substance use disorders; pharmacotherapy for substance use disorders; clinical pharmacology of drugs of abuse; drug–drug interactions; and co-occurring HIV disease, hepatitis C infection, and addiction.
Guest Editor: HIV and viral hepatitis medications, Antibacterials and antifungals, Antimalarials
Dr Gruber is a licensed psychologist and Clinical Professor in the Department of Psychiatry at the University of California San Francisco. Her work has focused on developing culturally competent, trauma-informed substance abuse and mental health services for low-income substance users with HIV and other chronic medical conditions. She has published research on psychosocial interventions in methadone maintenance, outpatient, and residential treatment settings, and on interactions of buprenorphine and alcohol with HIV medications.
Guest Editor: Anti-arrhythmic/cardiovascular drugs
Professor Haigney is Professor of Medicine and Pharmacology at the F Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA. As a cardiologist, his work investigates the mechanisms of sudden cardiac death. He recently participated on an expert panel to evaluate QT interval screening procedures for patients prescribed methadone.
Guest Editor: Benzodiazepines and non-benzodiazepine hypnotics
Professor Lintzeris has worked as a clinician and researcher in addiction medicine for over 25 years, and is currently the Director of Drug and Alcohol Services for South East Sydney Local Health District and Clinical Director of the Lambert Initiative in Cannabinoid Therapeutics at the University of Sydney. He is also a leading author of the Australian clinical guidelines for opioid treatment and the Australian Opioid Substitution Training Programme for medical practitioners, and has served as Chief Addiction Medicine Specialist for the NSW Ministry of Health, Australia.
Guest Editor: Anticonvulsants and mood stabilisers, Antipsychotics, Psychostimulants
Dr Sevarino is currently Medical Director of the Newington Mental Health Care Firm, Connecticut VA Healthcare System and an attending psychiatrist for the Substance Abuse Day Program at the VA Connecticut Healthcare System. He is involved in developing new treatments for substance abuse and is certified in Psychosomatic Medicine, and Addiction Medicine. Dr Sevarino is Member-at Large for the Academy of Addiction Psychiatry (AAAP) Board of Directors and has been Course Director for the AAAP Board Review Courses in Addictions since 2007.
Guest Editor, First edition: Antidepressants and anxiolytics, Antiemetics, Miscellaneous
Professor Nutt is currently Professor of Neuropsychopharmacology and director of the Neuropsychopharmacology Unit at Imperial College London. He has previously been Chief of the Section of Clinical Science in the National Institute of Alcohol Abuse and Alcoholism in the USA and is currently Chair of the Independent Scientific Committee on Drugs (ISCD) in the UK. In addition he is a Fellow of the Royal Colleges of Physicians and Psychiatrists and a Fellow of the Academy of Medical Sciences. In 2010 The Times Eureka science magazine included him in the 100 most important figures in British Science, and the only psychiatrist.
Peer review, First edition:
Europad (European Opiate Addiction Treatment Association) is a European society for professionals interested in the development of effective opiate addiction treatments. It produces the peer-reviewed journal, Heroin Addiction and Related Clinical Problems, and runs a biannual meeting bringing together some of the most influential international speakers in the field of addiction medicine.